Iambic Therapeutics (IAM) investor relations material

Company overview and business model

• Technology and clinical-stage life sciences company integrating proprietary AI with automated chemistry and biology for drug discovery.

• Platform, called molecular superintelligence, unifies drug discovery from hit identification to clinical developability.

• Proprietary technologies include Enchant (multimodal AI for property prediction) and NeuralPLexer (generative AI for structure prediction).

• Business model combines wholly owned drug development with revenue-generating partnerships with pharma and tech companies.

• Partnerships with AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer.

Financial performance and metrics

• Collaboration revenue: $12.8M (six months ended June 30, 2026), $9.4M (2025), $1.2M (2024).

• Net losses: $50.1M (six months ended June 30, 2026), $77.3M (2025), $47.9M (2024).

• Accumulated deficit: $245.3M as of June 30, 2026.

• Cash and cash equivalents: $207.9M as of June 30, 2026.

• Raised $461.8M in capital from investors including Catalio, Nexus Ventures, Q Healthcare Holding, NVIDIA, and Coatue Ventures.

Use of proceeds and capital allocation

• Net proceeds from IPO to fund clinical development of IAM1363, IAM217, and IAM-C1, with remainder for working capital and general corporate purposes.

• May use a portion for acquisitions or investments, though no current agreements exist.